H

Horizon Therapeutics PLC
F:HPR

Watchlist Manager
Horizon Therapeutics PLC
F:HPR
Watchlist
Price: 110.2 EUR Market Closed
Market Cap: 25.3B EUR

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of HPR.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HPR Intrinsic Value
Not Available
H
Base Case Scenario
Compare HPR to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about HPR?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Horizon Therapeutics PLC

Current Assets 3.9B
Cash & Short-Term Investments 2.5B
Receivables 717.4m
Other Current Assets 739.9m
Non-Current Assets 5.4B
PP&E 504.2m
Intangibles 4.3B
Other Non-Current Assets 565.4m
Current Liabilities 917.7m
Accounts Payable 85.5m
Accrued Liabilities 816.1m
Other Current Liabilities 16m
Non-Current Liabilities 3.1B
Long-Term Debt 2.5B
Other Non-Current Liabilities 528.6m
Efficiency

Free Cash Flow Analysis
Horizon Therapeutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Horizon Therapeutics PLC

Revenue
3.6B USD
Cost of Revenue
-903.4m USD
Gross Profit
2.7B USD
Operating Expenses
-2.2B USD
Operating Income
567.6m USD
Other Expenses
-129.6m USD
Net Income
438m USD
Fundamental Scores

HPR Profitability Score
Profitability Due Diligence

Horizon Therapeutics PLC's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Strong 3Y Average Gross Margin
Positive 3Y Average ROE
Healthy Operating Margin
46/100
Profitability
Score

Horizon Therapeutics PLC's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

HPR Solvency Score
Solvency Due Diligence

Horizon Therapeutics PLC's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
High Altman Z-Score
Low D/E
Long-Term Solvency
62/100
Solvency
Score

Horizon Therapeutics PLC's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HPR Price Targets Summary
Horizon Therapeutics PLC

There are no price targets for HPR.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for HPR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y